National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Neratinib (Nerlynx®) HTA ID: 19057

Neratinib is indicated for the extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.

 

NCPE Assessment Process Complete
Rapid review commissioned 18/12/2019
Rapid review completed 30/01/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of neratinib compared with the current standard of care.

 

Full pharmacoeconomic assessment commissioned by the HSE 05/02/2020
Pre-submission consultation with Applicant 21/04/2020
Initial submission received from Applicant 14/07/2020
Current status Initial submission received from Applicant